Is AbbVie Stock a Buy?

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to failed its clinical trials. Investors are also on edge over how the Trump administration and new Secretary of Health and Human Services Robert F. Kennedy Jr. might treat AbbVie and other U.S. pharmaceutical companies.AbbVie bounced back after strong fourth-quarter results, but tariff fears and market volatility have sent shares tumbling again. Today, AbbVie's stock sits roughly 20% off its highs. It's a good time to take a breather, assess the underlying business, and consider whether the stock's decline offers enough value to make AbbVie a buy despite all this noise.Here is what you need to know.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool